| 摘要 |
The present invention relates to methods of treating or preventing an inflammatory or immune disorder in a subject while eliminating or reducing the toxicity associated with the administration of cyclosporin A, comprising systemically administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically-acceptable carrier or excipient: in Formula I, the Formula for residue A is: where X is absent, -C1-C6 alkyl-, or -C3-C6 cycloalkyl-; Y is selected from the groups: -C(O)-O-R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy or halogen substituted C1-C6 alkylthio; -C(O)-S-R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy or halogen substituted C1-C6 alkylthio; -C(O)-OCH2-OC(O)R2 where R2 is C1-C6 alkyl optionally substituted with halogen, C1-C6 alkoxy, C1-C6 alkylthio, heterocyclics, or aryl; -C(S)-O-R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics, aryl, C1-C6 alkoxy or C1-C6 alkylthio, halogen substituted C1-C6 alkoxy or halogen substituted C1-C6 alkylthio; and -C(S)-S-R1 where R1 is hydrogen, C1-C6 alkyl optionally substituted with halogen, heterocyclics
|
